Ozempic tablets (semaglutide)
Ozempic tablets are a daily tablet of semaglutide made by Novo Nordisk. Their approved use in the U.S. is type 2 diabetes. They are the renamed second Rybelsus formulation, and they are not the Wegovy pill.
Educational information. This page does not give dosing instructions or tell you what to take. The current label and a prescriber decide that.
What Ozempic tablets are
- Generic name
- Semaglutide
- Maker
- Novo Nordisk
- Form
- Daily tablet
- U.S. approved use
- Type 2 diabetes
- First U.S. approval
- 2024, as a Rybelsus formulation. Renamed Ozempic tablets in 2026.
How it differs from related products
Ozempic tablets are daily oral semaglutide tablets approved for type 2 diabetes. They share a label with Rybelsus tablets, but the products come in different strengths and the label says they are not substitutable on a mg-to-mg basis. They are also not the Wegovy pill, a separate oral semaglutide product approved for weight management. The Ozempic injection is a different form of Ozempic, taken weekly.
| Product | Form | U.S. approved use | Status |
|---|---|---|---|
| Wegovy | Weekly injection | Weight management | FDA-approved for weight management |
| Wegovy HD | Weekly injection (higher strength) | Weight management | FDA-approved for weight management |
| Wegovy pill | Daily tablet | Weight management | FDA-approved for weight management |
| Ozempic | Weekly injection | Type 2 diabetes | FDA-approved, but not for obesity |
| Rybelsus | Daily tablet | Type 2 diabetes | FDA-approved, but not for obesity |
| Ozempic tablets (this page) | Daily tablet | Type 2 diabetes | FDA-approved, but not for obesity |
Where the name came from
Ozempic tablets began as a second formulation of Rybelsus, called R2. The FDA approved that formulation on December 9, 2024. On January 30, 2026 the FDA approved a labeling change that renamed the product from Rybelsus (formulation R2) to Ozempic (semaglutide) tablets.
Novo Nordisk began rolling the tablets out in the U.S. under the Ozempic name on May 4, 2026, according to trade press (Fierce Pharma, May 1, 2026). What happened to the Rybelsus name is covered on the Rybelsus page.
What the label says about strengths
The label the Atlas read (version 1/2026) covers both Ozempic tablets and Rybelsus tablets. It lists Ozempic tablets in 1.5, 4 and 9 mg and Rybelsus tablets in 3, 7 and 14 mg, and it says the two are not substitutable on a mg-to-mg basis. This atlas gives no conversion between them and does not advise on changing products.
What it is approved for
- Improving blood sugar control, along with diet and exercise, in adults with type 2 diabetes
- Reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them
A prescriber using a diabetes-approved product to treat weight is using it off-label. This atlas does not advise on that, and its weight-loss figures are not from studies of this product.
How it is taken
Per the label, the tablet is taken once a day in the morning on an empty stomach, with plain water (up to 4 ounces). The label says to wait at least 30 minutes before eating, drinking anything else or taking other oral medicines.
The label dose schedule, forms and missed-dose text for this product are quoted on the Ozempic dosage page. All four brands are side by side on the GLP-1 dosage chart.
What the trials found
The weight-loss trial figures in this atlas come from studies of the weight-management products. They are not shown here because they were not studies of Ozempic tablets' approved use.
Safety
Warnings, side effects and open questions for semaglutide are on the semaglutide page. The official label is the controlling source. The label for these tablets carries a boxed warning about the risk of thyroid C-cell tumors.
Compiled from public information: FDA-approved labels, manufacturer websites, ClinicalTrials.gov and published journal articles. Sources are listed at the bottom of this page.
Related
Semaglutide
The generic page: how it works, safety, and what is still unknown.
Wegovy
Wegovy and Ozempic both contain semaglutide as a weekly injection, but they are separate products with different approved uses.
Wegovy HD
Wegovy HD is a higher-strength version of the Wegovy weekly injection.
Wegovy pill
The Wegovy pill contains the same drug as the Wegovy injection, but as a daily tablet instead of a weekly injection.
Ozempic
Ozempic contains semaglutide, the same drug as Wegovy.
Rybelsus
Rybelsus is the original brand of oral semaglutide for type 2 diabetes, and Novo Nordisk has said it will not carry the brand forward in the U.S.
Follow Novo Nordisk
See every Novo Nordisk weight-loss and diabetes medicine, its trials, recent company statements and upcoming events in the Novo Nordisk obesity and diabetes tracker.
Sources
- Ozempic and Rybelsus (semaglutide) tablets: prescribing information Novo Nordisk, on DailyMed (U.S. National Library of Medicine). Label version 1/2026. Official FDA label on DailyMed
- FDA approval letter for Rybelsus supplements S-020 and S-021 (NDA 213051), December 9, 2024 U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Supplement S-020 adds the Rybelsus R2 formulation. Regulator
- FDA approval letter for supplement S-030 (NDA 213051), January 30, 2026 U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Approves a labeling change from the name Rybelsus (formulation R2) to Ozempic (semaglutide) tablets. Regulator
- Novo Nordisk's Rybelsus brand officially retired in the U.S. as the Ozempic pill takes branding center stage Fierce Pharma, May 1, 2026. Trade press report quoting a Novo Nordisk senior vice president. Trade press, secondary source
- DailyMed: current FDA drug labels U.S. National Library of Medicine. Regulator
- Drugs@FDA: approved drug products U.S. Food and Drug Administration. Regulator